How do you design a cell-type-specific promoter for AAV gene therapy?
Annogen designs cell-type-restricted promoters by functionally measuring cis-regulatory activity across target and off-target cells with SuRE, not by inferring it from chromatin marks.
VectorY’s VTx-002, featuring an Annogen promoter, cleared for ALS clinical trials phase 1&2
Advanced therapies VectorY’s VTx-002, featuring an Annogen promoter, cleared for ALS clinical trials phase 1&2 27 July 2026 Annogen is proud to announce a major milestone for our partner, VectorY Therapeutics, following the U.S. FDA’s IND clearance to proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002. This first-in-class vectorized antibody targets pathological TDP-43, the protein driving up […]
Case VectorY’s VTx-002
Advanced therapies VectorY’s VTx-002, featuring an Annogen promoter, cleared for ALS clinical trials phase 1&2 27 July 2026 Annogen is proud to announce a major milestone for our partner, VectorY Therapeutics, following the U.S. FDA’s IND clearance to proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002. This first-in-class vectorized antibody targets pathological TDP-43, the protein driving up […]
VectorY’s Clinical Milestone and the Shift Towards Experimentally Validated Promoters
Advanced therapies VectorY’s Clinical Milestone and the Shift Towards Experimentally Validated Promoters 27 July 2026 This week, the ALS community reached a significant milestone. Our partner, VectorY Therapeutics, announced the first patient has been dosed in their Phase 1/2 PIONEER-ALS clinical trial for VTx-002. VTx-002 represents a potential paradigm shift in treating Amyotrophic Lateral Sclerosis (ALS) […]
Annogen’s AIM™ screen: bespoke expression locus identification for more effective cell therapies
Advanced therapies Annogen’s AIM™ screen: bespoke expression locus identification for more effective cell therapies 27 July 2026 Annogen’s AIM™ screen revolutionizes the level of control researchers have over transgene expression by identifying optimal genomic loci for transgene integration. Choosing the integration site with the right expression profile will enable safer and more effective cell and […]
SuRE™ promoter screening: customizing your therapy for improved safety and efficacy
Advanced therapies SuRE™ promoter screening: customizing your therapy for improved safety and efficacy 27 July 2026 standing the challenge: the right place, the right time The development of cell and gene therapies is a complex and time-consuming process that depends on therapeutic genes being expressed in the right tissues, at the right time and at […]
What Distinguishes Annogen In Gene Promoter Design?
Advanced therapies What Distinguishes Annogen In Gene Promoter Design? 27 July 2026 What makes Annogen’s promoter design stand-out from other providers? A valid question. Let’s put this in historical context. Gene promoter design is nothing new: as early as the 1980’s, researchers began to understand different components within promoters, e.g. TATA box and transcription factor […]
Why promoter design is no longer just an expression checkbox, it’s the key to therapeutic endurance:
Advanced therapies Why promoter design is no longer just an expression checkbox, it’s the key to therapeutic endurance. 15 June 2026 As the cell and gene therapy (CGT) space matures and commoditizes, many low-hanging fruits have been picked. We are now facing another frontier in biology: getting a gene into a cell is one thing; […]
JURA Bio and Annogen Announce Research Collaboration to Advance Precision Gene Expression Engineering Through AI-Driven Design and Functional Genomics
Partnership brings together JURA’s variational synthesis platform and Annogen’s SuRE™ technology to unlock new possibilities for safer, more effective advanced therapies.
Twist Webinar: Bespoke Functional Genomics for AI
Dr. Joris van Arensbergen, Founder & CEO of Annogen, on how SuRE™ datasets support the design of DNA regulatory elements — and how Twist Bioscience’s oligo synthesis platform unlocks screening at unprecedented scale.
